Summary & Overview
HCPCS J0256: Alpha 1 Proteinase Inhibitor (Human) Injection, 10 mg
HCPCS Level II code J0256 designates a 10 mg vial of human alpha 1 proteinase inhibitor delivered by injection. This biologic replacement therapy is used in clinical contexts such as alpha-1 antitrypsin deficiency and represents a high-cost, specialty injectable product that impacts pharmacy and medical benefit billing nationally. Clear coding for unit dosage is important for accurate reimbursement, inventory management, and clinical documentation. Key payers in the national landscape include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the code’s clinical role, the typical sites of service where product administration occurs, and the payers commonly relevant for coverage and reimbursement considerations. The publication also outlines common billing modifiers and service-line considerations, benchmarks for coding and charge description when available, and contextual clinical background to inform coding accuracy. Data not available in the input for taxonomies, ICD-10 pairings, and related codes is noted where applicable. This summary serves as a concise reference for billing staff, revenue cycle professionals, and policy analysts who manage or review claims involving injectable alpha 1 proteinase inhibitor products.
Billing Code Overview
HCPCS Level II code J0256 represents the injection of alpha 1 proteinase inhibitor (human), not otherwise specified, 10 mg. This code describes a biologic replacement therapy product administered by injection for patients with alpha-1 antitrypsin deficiency or other clinical indications requiring proteinase inhibitor replacement.
Service Type: Injection / Biologic therapy
Typical Site of Service: Outpatient infusion or injection settings, including hospital outpatient departments, ambulatory infusion centers, physician offices, and other outpatient clinics where injectable biologic therapies are administered.
Clinical & Coding Specifications
Clinical Context
A 52-year-old patient with severe hereditary alpha-1 antitrypsin deficiency (emphysema due to alpha-1 antitrypsin deficiency) presents to an outpatient infusion clinic for maintenance augmentation therapy. The service consists of intravenous administration of alpha-1 proteinase inhibitor (human) supplied and billed by weight, with J0256 representing 10 mg units. The clinical workflow includes verification of the physician order and diagnosis, weight-based dose calculation, review of prior authorization and payor coverage, pre-infusion assessment (vital signs, allergy history), venous access placement (peripheral IV or existing port), preparation and reconstitution of the product by pharmacy, administration by an infusion nurse with monitoring for infusion reactions, documentation of lot numbers and dose given, and post-infusion observation prior to discharge. Typical sites of service are hospital outpatient infusion centers, ambulatory infusion suites, and specialty drug infusion clinics. Patient-specific documentation includes diagnosis supporting alpha-1 antitrypsin deficiency, dose calculation, consent, infusion record, and any infusion reactions or modifiers required for billing (for example, if service is rendered in an outpatient hospital setting or if the product is partially discarded).
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug amount discarded/not administered | Use when part of a single-use vial of the alpha-1 proteinase inhibitor is discarded and the discarded amount must be reported for payment or inventory reporting. |